Paul Shami, MD, is associate professor of oncology in the Department of Internal Medicine at the University of Utah and a staff physician at the Salt Lake City VA Medical Center, where he was chief of the Hematology/Oncology Section from 2002 to 2005. He is also an investigator and member of the Experimental Diagnostics and Therapeutics Program at Huntsman Cancer Institute.

As a specialist in adult hematology and oncology, Shami's main areas of interest include acute and chronic leukemias, lymphomas, and multiple myeloma. Over the past several years, Shami and investigators at the National Cancer Institute have studied ways to treat acute myeloid leukemia (AML) using nitric oxide-delivering agents with hopes to develop a new class of chemotherapeutic drugs for the treatment of this and other malignant diseases.

After receiving his doctorate from the American University of Beirut Faculty of Medicine in Beirut, Lebanon, Shami completed his residency with the Department of Internal Medicine at Duke University Medical Center. He then completed a fellowship with the Division of Hematology/Oncology at Duke University Medical Center and a research fellowship in the laboratory of hematopoietic cell biology at Duke University and the Durham VA Medical Centers under the mentorship of J. Brice Weinberg, MD.

Shami serves on numerous panels and committees, including the Acute Myeloid Leukemia panel and Chronic Myelogenous Leukemia panel of the National Cancer Center Network, the Leukemia Committee of the Southwest Oncology Group, and as chairman of the Patient Services Committee for the Utah chapter of the Leukemia and Lymphoma Society. He has published papers, book chapters, reviews, and abstracts related to his research, and has served as a grant reviewer and panelist for different medical journals. Shami has been with Huntsman Cancer Institute since 1998.